Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PE0116 in advanced solid tumors
NCT05800249Phase 1Completed
- Sponsor
- Shanghai HyaMab Biotechnology
- Start
- Mar 2021
- Primary completion
- Jun 2023
- Modality
- Monoclonal Antibodies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PE0116 in solid tumor, sponsored by Shanghai HyaMab Biotechnology. Primary endpoints: Occurrence of Drug Limited Toxicities at 28 days, Incidence of Treatment-emergent adverse events and serious adverse events and 1 more. Started Mar 2021; status: completed.
02
Drugs
PE0116
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05800249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05800249.